Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7

作者：

Ecke, Thorsten H. ^{[1
]}

机构：

[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany

来源：

ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷

关键词：

Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;

D O I：

10.1007/978-94-017-7215-0_18

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.

引用

页码：293 / 316

页数：24

共 50 条

[31] CARBOPLATIN VS. CISPLATIN-BASED CHEMOTHERAPY IN THE PERIOPERATIVE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER
Wosnitzer, Matthew
Hruby, Gregory
Cordon-Cardo, Carlos
Benson, Mitchell
Petrylak, Daniel
McKiernan, James
JOURNAL OF UROLOGY, 2010, 183 (04): : E658 - E659
[32] Adjuvant or Induction Cisplatin-Based Chemotherapy for Operable Lung Cancer
Besse, Benjamin
Le Chevalier, Thierry
ONCOLOGY-NEW YORK, 2009, 23 (06): : 520 - 527
[33] Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer
Khrunin, Andrey V.
Khokhrin, Denis V.
Moisseev, Alexey A.
Gorbunova, Vera A.
Limborska, Svetlana A.
PHARMACOGENOMICS, 2014, 15 (03) : 329 - 337
[34] THE ROLE OF CISPLATIN-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL TRACT CANCER
YAGODA, A
SEMINARS IN ONCOLOGY, 1989, 16 (04) : 98 - 104
[35] Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer
vanBasten, JPA
Hoekstra, HJ
vanDriel, MF
Sleijfer, DT
Droste, JHJ
Koops, HS
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (04) : 342 - 348
[36] Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer
Jean-Paul A. van Basten
Harald J. Hoekstra
Mels F. van Driel
Dirk Th. Sleijfer
Jos H. J. Droste
Heimen Schraffordt Koops
Annals of Surgical Oncology, 1997, 4 : 342 - 348
[37] A case of aortitis during cisplatin-based chemotherapy for cervical cancer
Webb, Katharine
Prakash, Vineet
Kirresh, Othman
Stewart, Alexandra
BJR CASE REPORTS, 2019, 5 (01):
[38] Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer
Galsky, Matthew D.
Krege, Susan
Lin, Chia-Chi
Hahn, Noah
Ecke, Thorsten H.
Moshier, Erin
Sonpavde, Guru
Godbold, James
Oh, William K.
Bamias, Aristotle
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 30.e15 - 30.e21
[39] Unraveling resistance to cisplatin-based chemotherapy
Laffman-Johnson, Elise
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) : 348 - 348
[40] INTRATESTICULAR EFFECTS OF CISPLATIN-BASED CHEMOTHERAPY
DIECKMANN, KP
LOY, V
EUROPEAN UROLOGY, 1995, 28 (01) : 25 - 30

← 1 2 3 4 5 →